Review
Copyright ©The Author(s) 2017.
World J Cardiol. Oct 26, 2017; 9(10): 773-786
Published online Oct 26, 2017. doi: 10.4330/wjc.v9.i10.773
Table 1 Current European Society of Cardiology recommendations for implantable cardioverter defibrillator implantation for primary prevention in patients with ischemic and non-ischemic left ventricular dysfunction
Recommendations
Class I: ICD therapy is recommended to reduce SCD in patients with symptomatic HF (NYHA class II–III) and LVEF ≤ 35% after ≥ 3 mo of optimal medical therapy who are expected to survive for at least 1 yr with good functional status
Level of evidence A: Ischemic etiology (at least 6 wk after myocardial infarction)
Level of evidence B: Non-ischemic etiology